CoChat

Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes

Open access

Published version of a preprint

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index; none of the 40 sources its claims cite is checked for support yet.

Abstract

Most COVID-19 vaccines elicit immunity against the SARS-CoV-2 Spike protein. However, Spike protein mutations in emerging strains and immune evasion by the SARS-CoV-2 virus demonstrates the need to develop more broadly targeting vaccines. To facilitate this, we use mass spectrometry to identify immunopeptides derived from seven relatively conserved structural and non-structural SARS-CoV-2 proteins (N, E, Nsp1/4/5/8/9). We use two different B-lymphoblastoid cell lines to map Human Leukocyte Antigen (HLA) class I and class II immunopeptidomes covering some of the prevalent HLA types across the global human population. We employ DNA plasmid transfection and direct antigen delivery approaches to sample different antigens and find 248 unique HLA class I and HLA class II bound peptides with 71 derived from N, 12 from E, 28 from Nsp1, 19 from Nsp4, 73 from Nsp8 and 45 peptides derived from Nsp9. Over half of the viral peptides are unpublished. T cell reactivity tested against 56 of the detected peptides shows CD8+ and CD4+ T cell responses against several peptides from the N, E, and Nsp9 proteins. Results from this study will aid the development of next-generation COVID vaccines targeting epitopes from across a number of SARS-CoV-2 proteins. The immune response to the spike protein of SARS-CoV-2 has been relatively well studied, but less is known about other viral proteins. Here, the authors identify immunopeptides from seven structural and non-structural SARS-CoV-2 proteins presented to the immune system by HLA molecules and confirm T-cell responses against some of them in convalescent individuals.

Overview

CoChat Summary

TL;DR

This study used mass spectrometry immunopeptidomics in two B-lymphoblastoid cell lines to map HLA class I and class II peptides derived from seven conserved SARS-CoV-2 proteins (N, E, Nsp1/4/5/8/9), identifying 248 unique viral peptides, over half previously unpublished. T cell assays in convalescent donors confirmed CD4+ and CD8+ responses against several N, E, and Nsp9 peptides, supporting broader T-cell-based vaccine design.

Key findings

  • Across stable transfection and direct antigen delivery, 248 unique HLA class I/II-bound SARS-CoV-2 peptides were identified: 71 from N, 12 from E, 28 from Nsp1, 19 from Nsp4, 73 from Nsp8, and 45 from Nsp9; over half were unpublished.
  • Stable transfection of BLCLs yielded 181 non-redundant SARS-CoV-2 peptides; direct protein delivery yielded 81 unique peptides. Nsp8 and Nsp9 were efficiently presented, with 78% and 85% sequence coverage, respectively, in the 9004 and 9087 BLCL immunopeptidomes.
  • Of 56 tested synthetic peptides, T cell reactivity was detected against several peptides from N, E, and Nsp9. CD4+ responses included nested E57-65/E58-73, Nsp1 88-99/89-97, and Nsp9 45-55/45-59; a dominant CD4+ response to N343-361 occurred in three donors. A CD8+ response was narrowed to N71-85, N77-86, and N77-87.
  • Binding prediction assigned 53% (105/200) of PTM-stripped viral immunopeptides as binders to at least one expressed HLA allotype; 43/200 peptides had similarity to human protein-derived peptides (up to two mismatches). Twelve antigen presentation hotspots were identified.

Methods

  • Two EBV-transformed B-LCLs (IHW09004 and IHW09087) expressing common HLA class I/II allotypes were used. Antigens were introduced by stable transfection with plasmids encoding N, E, Nsp8, and Nsp9, or by direct electroporation of recombinant N, Nsp1, Nsp4, Nsp5, and Nsp9 proteins.
  • HLA class I and class II peptide complexes were immunoaffinity-purified with W6/32 and a mix of SPV-L3/B7/21/LB3.1 antibodies, respectively, then analyzed by LC-MS/MS on a Bruker timsTOF Pro with PASEF. Data were searched with PEAKS Online 10 against human and SARS-CoV-2 proteomes at 5% FDR, with 1% FDR re-testing for viral peptides.
  • T cell reactivity was tested using 56 synthetic peptides in pools with PBMCs from 9 convalescent donors collected 12–223 days post-infection; cells were expanded for 10 days, restimulated, and analyzed by intracellular cytokine staining for IFNγ/TNF. Binding predictions used netMHCpan/netMHCIIpan, and results were compared with IEDB.

Limitations

  • Stated: T cell validation was limited to nine donors with variable HLA allotypes, and larger cohorts are needed to assess immunodominance. The direct delivery approach may not capture mammalian post-translational modifications if bacterially expressed protein is used, and it directs presentation predominantly to HLA class II; B cells may also be less efficient at cross-presentation.
  • Stated: the study does not resolve what determines antigen processing/presentation hotspots, and further work is needed on proteasome processivity, PTMs, and antigen structure.
  • Evident from the text: only two B-LCLs were profiled, T cell assays covered only 56 of 248 detected peptides, and no in vivo protection or vaccine efficacy was tested.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-024-51959-6

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Workflow for the generation of SARS-CoV-2-derived HLA I and HLA II immunopeptidome data. A Upper panel depicts the large-scale workflow used for the stable transfection and processing of B lymphoblastoid cell lines (BLCL) cells using EF1α-GoI-pIRES-DsRed plasmids containing SARS-CoV-2 genes. Cell pellets (4 x 108 to 1 x 109) were homogenised using a cryomill, lysed, and peptide-HLA complexes immunoaffinity purified using first the W6/32 antibody (HLA class I) and subsequently a mix of SPV-L3, LB3.1, B7/21 antibodies (HLA class II). Peptides were separated from HLA using reverse-phase high-performance liquid chromatography (HPLC). B The lower panel shows the workflow schematic for small-scale protein antigen direct delivery experiments. SARS-CoV-2-derived proteins were electroporated into BLCL and 0.9 ×108 to 1.6 × 108 cells collected 48 h later. Cell pellets were subjected to direct lysis and immunoaffinity purification. Peptides were separated from HLA using 5 kilodalton (kDa) molecular weight cut-off filters. All samples were analysed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and PASEF® on TimsTOF Pro. MHC: Major histocompatibility complex. Created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license.
Fig. 1 Workflow for the generation of SARS-CoV-2-derived HLA I and HLA II immunopeptidome data. A Upper panel depicts the large-scale workflow used for the stable transfection and processing of B lymphoblastoid cell lines (BLCL) cells using EF1α-GoI-pIRES-DsRed plasmids containing SARS-CoV-2 genes. Cell pellets (4 x 108 to 1 x 109) were homogenised using a cryomill, lysed, and peptide-HLA complexes immunoaffinity purified using first the W6/32 antibody (HLA class I) and subsequently a mix of SPV-L3, LB3.1, B7/21 antibodies (HLA class II). Peptides were separated from HLA using reverse-phase high-performance liquid chromatography (HPLC). B The lower panel shows the workflow schematic for small-scale protein antigen direct delivery experiments. SARS-CoV-2-derived proteins were electroporated into BLCL and 0.9 ×108 to 1.6 × 108 cells collected 48 h later. Cell pellets were subjected to direct lysis and immunoaffinity purification. Peptides were separated from HLA using 5 kilodalton (kDa) molecular weight cut-off filters. All samples were analysed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and PASEF® on TimsTOF Pro. MHC: Major histocompatibility complex. Created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license.CC BY-NC-ND · PubMed Central
Fig. 2 Immunopeptidomic profile of class I and class II eluted peptides presented by stably transfected BLCL. Samples were analysed using PEAKS Online using a 5% FDR cut-off. A Relevant eluted peptide numbers, headers in bold. B Mean length distribution of class I and class II eluted peptides, SD is shown, based on all n = 5 cell lines in A; 9087: black bars, 9004: blue bars. C Representative Gibbs Cluster peptide motif analysis of 9-mers from the HLA class I elution of 9087_E is shown. Attribution of individual clusters to known HLA class I alleles expressed in 9087 is shown above each cluster, clusters are based on 1130-5414 peptides. Analysis using Immunolyser53. Nsp: non-structural protein, BLCL: B lymphoblastoid cell line, HLA: human leukocyte antigen. Source data are provided as a Source Data file.
Fig. 2 Immunopeptidomic profile of class I and class II eluted peptides presented by stably transfected BLCL. Samples were analysed using PEAKS Online using a 5% FDR cut-off. A Relevant eluted peptide numbers, headers in bold. B Mean length distribution of class I and class II eluted peptides, SD is shown, based on all n = 5 cell lines in A; 9087: black bars, 9004: blue bars. C Representative Gibbs Cluster peptide motif analysis of 9-mers from the HLA class I elution of 9087_E is shown. Attribution of individual clusters to known HLA class I alleles expressed in 9087 is shown above each cluster, clusters are based on 1130-5414 peptides. Analysis using Immunolyser53. Nsp: non-structural protein, BLCL: B lymphoblastoid cell line, HLA: human leukocyte antigen. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 3 Immunopeptidomic profile of class I and class II eluted peptides presented by BLCL 48 h after direct delivery of protein antigen. Samples were analysed using PEAKS Online using a 5% FDR cut-off. A Relevant eluted peptide numbers, headers in bold. B Mean length distribution of HLA I and HLA II eluted peptides. SD is shown, based on all n = 5 cell lines in A; 9087: black bars, 9004: blue bars. C Representative Gibbs Cluster peptide motif analysis of 9-mers from an HLA class I elution of 9004 with delivery of Nucleoprotein is shown. HLA-A*02:01-derived peptides dominate the HLA class I immunopeptidome, cluster size is 2602 peptides. Analysis using Immunolyser53. Nsp non-structural protein, BLCL B lymphoblastoid cell line, HLA human leukocyte antigen. Source data are provided as a Source Data file.
Fig. 3 Immunopeptidomic profile of class I and class II eluted peptides presented by BLCL 48 h after direct delivery of protein antigen. Samples were analysed using PEAKS Online using a 5% FDR cut-off. A Relevant eluted peptide numbers, headers in bold. B Mean length distribution of HLA I and HLA II eluted peptides. SD is shown, based on all n = 5 cell lines in A; 9087: black bars, 9004: blue bars. C Representative Gibbs Cluster peptide motif analysis of 9-mers from an HLA class I elution of 9004 with delivery of Nucleoprotein is shown. HLA-A*02:01-derived peptides dominate the HLA class I immunopeptidome, cluster size is 2602 peptides. Analysis using Immunolyser53. Nsp non-structural protein, BLCL B lymphoblastoid cell line, HLA human leukocyte antigen. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 4 Distribution of HLA-I and HLA-II presented protein regions within SARS-CoV-2 derived investigated proteins. A SARS-CoV-2 derived peptides found across stable transfected (TF) B lymphoblastoid cell lines (BLCL) and direct delivery (DD) antigen approaches and their alignment to source proteins. Peaks represent mutations in variants of concern. B Table of antigen presentation hotspots. Peptide sequences derived from human leukocyte antigen (HLA) class I elutions are underlined, peptide sequences derived from HLA class II elutions are shown in bold italic. Nsp: non-structural protein, Source data are provided as a Source Data file.
Fig. 4 Distribution of HLA-I and HLA-II presented protein regions within SARS-CoV-2 derived investigated proteins. A SARS-CoV-2 derived peptides found across stable transfected (TF) B lymphoblastoid cell lines (BLCL) and direct delivery (DD) antigen approaches and their alignment to source proteins. Peaks represent mutations in variants of concern. B Table of antigen presentation hotspots. Peptide sequences derived from human leukocyte antigen (HLA) class I elutions are underlined, peptide sequences derived from HLA class II elutions are shown in bold italic. Nsp: non-structural protein, Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 5 Comparison of data generated in the current study and data available in IEDB. Ligands identified by immunopeptidomics in the current study were compared to those deposited in the Immune Epitope Database (IEDB) for SARS-CoV-2 reading frames (A) and HLA restriction (B). The same data represented as an alignment to source proteins shows the ligand coverage of proteins analysed in the current study and the ligand/epitope coverage from the data annotated in IEDB, divided by MHC Class I or II restriction (C). IEDB epitopes were restricted to ELISPOT, intracellular staining and multimer staining assay types. Nsp: non-structural protein, HLA human leukocyte antigen, MHC Major histocompatibility complex. Source data are provided as a Source Data file.
Fig. 5 Comparison of data generated in the current study and data available in IEDB. Ligands identified by immunopeptidomics in the current study were compared to those deposited in the Immune Epitope Database (IEDB) for SARS-CoV-2 reading frames (A) and HLA restriction (B). The same data represented as an alignment to source proteins shows the ligand coverage of proteins analysed in the current study and the ligand/epitope coverage from the data annotated in IEDB, divided by MHC Class I or II restriction (C). IEDB epitopes were restricted to ELISPOT, intracellular staining and multimer staining assay types. Nsp: non-structural protein, HLA human leukocyte antigen, MHC Major histocompatibility complex. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 6 CD4+ and CD8 + T cell reactivity towards detected SARS-CoV-2 peptides. A Representative concatenated FACS plots of IFNγ expression in Donor 1 CD4+ and Donor 7 CD8 + T cells in response to peptide pools 1, 2, 3 (left). Frequency of IFNγ + CD4+ and CD8 + T cells across donors following stimulation with peptide pools (background DMSO subtracted). Percentage IFNγ+ of CD4+ and CD8 + T cells depicted as a heatmap (middle) and median with 95% CI is shown (n = 9 donors, mean with SD; right). B Representative FACS plots of CD4 + T cell IFNy+ response (left) of Donor 3. Frequency of IFNγ + TNF + CD4 + T cells after stimulation with individual pool 1 SARS-CoV-2 peptides (right). C Representative FACS plots for CD4 + T cell response to N343-361 (left). Frequency of IFNγ + CD4 + T cells stimulated with pool 2 individual peptides (background DMSO subtracted, n = 5 donors, mean with SD; top). Frequency of IFNγ + TNF + CD4 + T cells after stimulation with DMSO and N343-361 (bottom). D Representative FACS plot of IFNγ + CD8 + T cells (top). IFNγ + TNF+ expression in response to stimulation with peptide pool 3 subpools (bottom). D10/D13 day 10/13, CD cluster of differentiation, IFN interferon, TNF Tumor necrosis factor, DMSO dimethyl sulfoxidy, Nsp non-structural protein. Source data are provided as a Source Data file.
Fig. 6 CD4+ and CD8 + T cell reactivity towards detected SARS-CoV-2 peptides. A Representative concatenated FACS plots of IFNγ expression in Donor 1 CD4+ and Donor 7 CD8 + T cells in response to peptide pools 1, 2, 3 (left). Frequency of IFNγ + CD4+ and CD8 + T cells across donors following stimulation with peptide pools (background DMSO subtracted). Percentage IFNγ+ of CD4+ and CD8 + T cells depicted as a heatmap (middle) and median with 95% CI is shown (n = 9 donors, mean with SD; right). B Representative FACS plots of CD4 + T cell IFNy+ response (left) of Donor 3. Frequency of IFNγ + TNF + CD4 + T cells after stimulation with individual pool 1 SARS-CoV-2 peptides (right). C Representative FACS plots for CD4 + T cell response to N343-361 (left). Frequency of IFNγ + CD4 + T cells stimulated with pool 2 individual peptides (background DMSO subtracted, n = 5 donors, mean with SD; top). Frequency of IFNγ + TNF + CD4 + T cells after stimulation with DMSO and N343-361 (bottom). D Representative FACS plot of IFNγ + CD8 + T cells (top). IFNγ + TNF+ expression in response to stimulation with peptide pool 3 subpools (bottom). D10/D13 day 10/13, CD cluster of differentiation, IFN interferon, TNF Tumor necrosis factor, DMSO dimethyl sulfoxidy, Nsp non-structural protein. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 1 Not valid · 23 Not checked · 77 Own results and interpretations

45 more claims

Create a free account to see all 101 claims and to verify the 40 references still open.

See all claims — free account
  • It may state two separate claims as one. 41
  • Probably not a substantial claim. 20

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 56 references

Cited by

See all 12

Metadata

Authors
Braun, A., Rowntree, L. C., Huang, Z., Pandey, K., Thuesen, N., Li, C., Petersen, J., Littler, D. R., Raji, S., Nguyen, T. H. O., Jappe Lange, E., Persson, G., Schantz Klausen, M., Kringelum, J., Chung, S., Croft, N. P., Faridi, P., Ayala, R., Rossjohn, J., Illing, P. T., Scull, K. E., Ramarathinam, S., Mifsud, N. A., Kedzierska, K., Sørensen, A. B., & Purcell, A. W.
Affiliations
  • Monash University (AU)
  • The University of Melbourne (AU)
Corresponding author
Purcell, Anthony W.
Venue
Nature Communications
Published
2024-08-30
Volume
15
Issue
1
Pages
7547-7547
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4402044597
Cited by
12
References
56
Citations by year
2026: 5 · 2025: 5 · 2024: 2
FWCI
1.12
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by-nc-nd)
  • Research Square (submittedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion, cc-by-nc-nd)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
Funders
  • National Psoriasis Foundation (817907)
  • Innovationsfonden
  • Rebecca L. Cooper Medical Research Foundation (PG2020775)
  • Monash University
  • Medical Research Council
  • National Health and Medical Research Council (2016596, 1194036, 2026357, 1143366, 1173871)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords
SARS-CoV-2, immunopeptidome, HLA class I, HLA class II, viral peptides, non-structural proteins, nsp9, nsp8, NSP4, Nsp1, envelope protein, nucleocapsid protein, T cell epitopes, CD8+ T cells, CD4+ T cells, COVID-19 vaccines, HLA haplotypes, B-lymphoblastoid cell lines, convalescent patients
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, Histocompatibility Antigens Class II, Antigens, Viral, Cell Line, Haplotypes, HLA Antigens, Humans, Peptides, Histocompatibility Antigens Class I, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Epitopes, T-Lymphocyte, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes. https://app.cochat.ai/papers/10.1038/s41467-024-51959-6
The paper
Braun, A., Rowntree, L. C., Huang, Z., Pandey, K., Thuesen, N., Li, C., Petersen, J., Littler, D. R., Raji, S., Nguyen, T. H. O., Jappe Lange, E., Persson, G., Schantz Klausen, M., Kringelum, J., Chung, S., Croft, N. P., Faridi, P., Ayala, R., Rossjohn, J., . . . Purcell, A. W. (2024). Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes. Nature Communications. https://doi.org/10.1038/s41467-024-51959-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.